Pyoderma Gangrenosum Following Cytosine Arabinoside, Aclarubicin and Granulocyte Colony-Stimulating Factor Combination Therapy in Myelodysplastic Syndrome.

Takagi, Satoshi; Ohsaka, Akimichi; Taguchi, Hirohisa; Kusama, Hiroshi; Matsuoka, Takeshi

doi:10.2169/internalmedicine.37.316

Cited by 12 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cases of drug‐induced PG were mainly gathered from PubMed searches using a variety of combined search terms including ‘pyoderma gangrenosum’, ‘drug‐induced pyoderma gangrenosum’, ‘neutrophilic dermatosis’, ‘treatment’ and ‘therapy’. A list of cases of drug‐induced PG is provided in Table and the proposed pathogenic mechanisms for each drug are illustrated in Figure .…”

Section: Summary Of Each Of the 43 Published Reports Of Drug‐induced mentioning

confidence: 99%

Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum

Patel

Ortega‐Loayza

2017

Br J Dermatol

View full text Add to dashboard Cite

This study aimed to explore how drug-induced pyoderma gangrenosum develops in the body. Pyoderma gangreno-sum (PG) is a rare autoinflammatory disease (a genetic disease caused by a malfunctioning immune system) that causes tissue cells to die, resulting in severe and painful ulcers. Drug-induced disease is where a disease occurs, or is triggered, as a result of taking medication/drugs. In this study 43 cases of patients diagnosed with drug-induced PG were reviewed. The authors found that most of the medications associated with drug-induced PG affected more the one element in the pathway that leads to a person developing drug-induced PG. Abnormal neutrophil migration and function, dysregulated inflammation, keratinocyte apoptosis, and alteration of epigenetic mechanisms were all found to be associated with the development of drug-induced PG. Abnormal neutrophil migration and function refers to the irregular movement and function of a specific type of white blood cell (which forms part of the body's immune system). Dysregulated inflammation refers to an abnormal inflammation response in the body's cells and tissue. Ker-atinocyte apoptosis means the death of keratinocyte cells (the cells that form the majority of the outer layer of skin). Alteration of epigenetic mechanisms means a change to the way in which a cell reads and understands its own genes, which in turn affects how the cell behaves. The authors conclude that, in order to better understand how PG develops, further research is needed into the immune system, epigenetics (the way in which a cell reads and acts upon its genes) and NETosis (a form of cell death).

show abstract

Section: Summary Of Each Of the 43 Published Reports Of Drug‐induced mentioning

confidence: 99%

Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum

Patel

Ortega‐Loayza

2017

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…63 Besides promoting myeloid haematopoiesis, GM-CSF stimulates the production of inflammatory mediators by macrophages and neutrophils, 64 as well as the proliferation of Th-17 cytokines. 65 Subcutaneous injections of G-CSF [66][67][68][69][70][71][72] have been associated with the development of PG in patients with underlying malignancy.…”

Section: Inflammation and Comorbiditiesmentioning

confidence: 99%

Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment

et al. 2015

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a neutrophil-predominant inflammatory disease that initially presents as a sterile pustule and may progress to ulcerations. Its root cause is unknown, but the presentation is commonly associated with systemic inflammatory conditions such as inflammatory bowel disease, arthritis and haematological abnormalities. On the other hand, pregnant women show a progressive neutrophilia during gestation, which culminates in a major inflammatory event to help drive labour. Although uncommonly, PG has been associated with pregnancy, which provides an additional link to systemic inflammation as an underlying cause of PG. We reviewed documented presentations of PG in gravid and post-partum patients, and have speculated on the possible pathogenesis based on their clinical presentations. Also, we summarize the reported treatments and their outcomes in these patients.

show abstract

“…[6][7][8] However, the association between G-CSF and cutaneous reactions is usually difficult to assess in patients because those who receive G-CSF are likely to have complex illnesses and to take other medications. [8][9][10] However, if such reactions are observed in a healthy individual receiving G-CSF, such as a PBSC donor, they are most likely due to G-CSF and could be evaluated as its adverse effects. In such healthy individuals, in addition to local cutaneous reactions at the site of injection, some cutaneous manifestations have also been reported.…”

Section: Discussionmentioning

confidence: 99%

Erythema exsudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor

Mori

Sato

Watanabe

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:We describe a healthy peripheral blood stem cell (PBSC) donor who developed a cutaneous reaction, erythema exsudativum multiforme, during the administration of granulocyte colony-stimulating factor (G-CSF) for mobilization. The cutaneous lesions were located on his hips, apart from the site of G-CSF injection. Treatment with topical corticosteroid was commenced, and the lesions resolved completely within a week. Adverse cutaneous reactions induced by G-CSF have been reported infrequently in healthy donors. Further documentation of cases and their full evaluation will be of great importance for both physicians and PBSC donor. Bone Marrow Transplantation (2000) 26, 239-240.

show abstract

Pyoderma Gangrenosum Following Cytosine Arabinoside, Aclarubicin and Granulocyte Colony-Stimulating Factor Combination Therapy in Myelodysplastic Syndrome.

Cited by 12 publications

References 12 publications

Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum

Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum

Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment

Erythema exsudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor

Contact Info

Product

Resources

About